Business Wire

AZ-WALTON

Share
Walton Expands U.S. Homebuilder BOLD Funds to Support Demand for New Single-Family Home Market

Walton, a real estate investment and land asset management company with US$3.39 billion under management and administration, has expanded its Builder Option Land Development Funds (BOLD Funds), with an investment objective of raising capital to acquire land identified by large U.S. homebuilders for near-term residential development projects.

The collective $500 million in BOLD Funds -- $250 million U.S. fund targeted at U.S. investors and a separate $250 million offshore fund targeted at non-U.S. resident investors -- provide an alternative investment into real estate assets that support the near-term land inventory needs of leading national homebuilders.

The newly expanded BOLD Funds offer investors, both domestic and internationally, the opportunity to participate in the current growth of the U.S. homebuilding market.

According to a John Burns Housing Survey, new home demand is on fire with June new home sales increasing 55% year-over-year (YOY.) Sales improved in all regions YOY, led by 84% in Florida, 59% in Texas and 54% in the Southeast. Exceeding 2018 and 2019 pricing strength, 57% of builders increased net prices in June, while traffic rating was the best it’s been in four years.

Average finished inventory fell 20% YOY as consumers clamored for quick move-ins and 55% of builders expect good sales in the next six months, compared to 36% one year ago.

The BOLD Funds intend to acquire properties identified by large publicly traded U.S. homebuilders for near-term residential development. The land is then expected to be sold to those same builders in phases with an agreed upon takedown schedule and flexible payment terms. The BOLD Funds expect to make distributions to investors as homes are developed and sold by the builders.

The primary investment objective of the BOLD Funds is to preserve capital investment and generate cash flow through the acquisition and sale of land assets. A purchase and sale agreement with the homebuilder is in place prior to each acquisition which defines the take-down schedule and price per phase. Properties are acquired on an all-cash basis and cash flow is forecast to commence within 6-24 months.

“Walton’s BOLD Funds meet the needs of an evolving homebuilding industry by allowing builders to tie up land inventory with option structures that offer a limited amount of capital down,” said Bill Doherty, CEO, Walton Group of Companies. “Homebuilders are able to improve their ROI by better aligning land inventory costs with cash flow from home sales and investors benefit from a diversified source of cash flow.”

The National Association of Home Builders (NAHB) Housing Market Index (HMI) released in mid-June, reported that builder confidence in the single-family new home market jumped 21 points to 58 in June 2020, also demonstrating that housing stands poised to lead a post-pandemic economic recovery. Any reading above 50 indicates a positive market, stated the Index.

“As the nation re-opens, housing is well-positioned to lead the economy forward,” said NAHB Chairman Dean Mon. “Inventory is tight, mortgage applications are increasing, interest rates are low, and confidence is rising. And buyer traffic more than doubled in one month even as builders report growing online and phone inquiries stemming from the outbreak,” Mon said.

For over 40 years, Walton has researched, planned and structured pre-development land investments located in the major growth corridors throughout the U.S. and Canada. The evolution of Walton has opened the door to offering new products, like its BOLD Funds, creating new opportunities for investors and homebuilders.

About Walton

Walton is a privately owned, leading global real estate investment, land asset management and administration company that has focused on strategically located land in major growth corridors for 40-plus years. The company manages and administers US$3.39 billion of real estate assets in North America, on behalf of its investors and business partners. Walton has more than 104,000 acres of land under ownership, management and administration in the United States and Canada. For more information on Walton, its entities and the company’s portfolio of assets, visit Walton.com.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye